Year: 2018
Type: review
Abstract: Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME.
Source: F1000Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,350
Awards: U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer, G132965223, G1727840030, Harnessing the power of exosomes for non-coding RNA delivery, MD Anderson Gynecologic SPORE for Uterine Cancers, Platelets promote growth of ovarian cancer, G4586139927, G5009597576, G5731630525, G6453487649, G9000006507, G9000303369, Cancer Center Support Grant
OpenAlex ID: W2792676381